OR WAIT null SECS
January 31, 2022
Article
The approval of the Spikevax vaccine was based on safety and efficacy data approximately 6 months after the second dose.
December 22, 2021
The relative risk reduction was 94% in patients 65 years of age or older in clinical trials.
December 15, 2021
Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP could boost users.
December 09, 2021
The data shows booster shots offer particularly strong protection against the variant.